Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic challenges in pathologic staging of renal cell carcinoma following systemic immunotherapy.

American journal of clinical pathologyĀ·2026
Same author

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

European urologyĀ·2026
Same author

Repeatability of Semi-Quantitative and Volumetric Features from Artificial-Intelligence-Guided Lesion Segmentation on <sup>18</sup>F-DCFPyL PSMA-PET/CT Images: Results from a Test-Retest Cohort.

Tomography (Ann Arbor, Mich.)Ā·2026
Same author

A small-molecule inverse agonist of PPARĪ³ for advanced solid tumors: a phase 1 trial.

Nature medicineĀ·2026
Same author

Current perspective on the impact of endogenous retroviruses in clear cell renal cell carcinoma.

Kidney cancer journal : official journal of the Kidney Cancer AssociationĀ·2026
Same author

APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.

Nature communicationsĀ·2025
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reportsĀ·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reportsĀ·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reportsĀ·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reportsĀ·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reportsĀ·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reportsĀ·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Improving Systemic Chemotherapy for Bladder Cancer.

Tracy L Rose1, Matthew I Milowsky2

  • 1Division of Hematology/Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, 170 Manning Drive, CB #7305, 27599, Chapel Hill, NC, USA.

Current Oncology Reports
|March 18, 2016
PubMed
Summary
This summary is machine-generated.

Systemic chemotherapy is crucial for muscle-invasive and metastatic bladder cancer (BCa). Advances in targeted agents and immunotherapy offer promising, less toxic treatment options for BCa patients.

Keywords:
Adjuvant therapyBiologic agentsBladder cancerChemotherapyImmunotherapyMolecular biologyNeoadjuvant therapyPersonalized therapyPrognostic factorsTargeted agentsTransitional cell carcinomaTrimodality therapyUrothelial carcinoma

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

Related Experiment Videos

Last Updated: Mar 24, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

Area of Science:

  • Oncology
  • Urology
  • Medical Chemistry

Background:

  • Systemic chemotherapy is a cornerstone in treating muscle-invasive and metastatic bladder cancer (BCa).
  • Cisplatin-based regimens are standard for metastatic BCa, with neoadjuvant chemotherapy increasingly used for muscle-invasive disease.
  • Adjuvant chemotherapy is an option for select patients who haven't received neoadjuvant therapy.

Purpose of the Study:

  • To review current systemic chemotherapy options for bladder cancer.
  • To highlight emerging targeted agents and immunotherapies for BCa treatment.
  • To discuss the role of chemotherapy in bladder preservation and metastatic disease.

Main Methods:

  • Review of current clinical practices and recent clinical trials in bladder cancer systemic therapy.
  • Analysis of data regarding cisplatin-based chemotherapy, targeted agents, and immunotherapy.
  • Evaluation of treatment outcomes in muscle-invasive, metastatic, and bladder-preserving contexts.

Main Results:

  • Cisplatin-based chemotherapy remains the standard for metastatic BCa.
  • Neoadjuvant chemotherapy is increasingly adopted for muscle-invasive BCa.
  • Immunotherapy shows potential for less toxic and more effective metastatic BCa treatment.

Conclusions:

  • Systemic chemotherapy is vital for various stages of bladder cancer.
  • Novel targeted therapies and immunotherapies are rapidly advancing BCa treatment.
  • Future research holds promise for improved systemic treatments for bladder cancer.